US Food and Drug Administration approval of esketamine and brexanolone
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. US Food and Drug Administration approval of esketamine and brexanolone Ioana A Cristea, Florian Naudet
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which led to the (S)-ketamine nasal spray (under the brand name Spravato®) receiving FDA approval in March of 2019 as an adjunct treatment for adults with treatment-resistant depression, or major depression with suicidal thoughts or actions”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Cristea & Naudet, 2019
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More concerningly, the FDA described in its assessment some possible data integrity issues for two trials [5].”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“two [9, 10] out of the 3 pivotal initiation RCTs [9–11] failed to demonstrate that esketamine was superior to placebo [5]”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Ketamine is recognised to have withdrawal effects, including lowered mood (dysphoria), fatigue, poor appetite, and anxiety.11”
From Are we repeating mistakes of the past? A review of the evidence for esketamine (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“This study design is problematic because withdrawal effects from the drug can be mistaken for relapse of depression.”
From Are we repeating mistakes of the past? A review of the evidence for esketamine (2021) · cites this paper as [11]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Milev, R. V., Giacobbe, P., Kennedy, S. H., Blumberger, D. M., Daskalakis, Z. J., Downar, J., Modirrousta, M., Patry, S., Vila-Rodriguez, F., Lam, R. W., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716660033 · Cited by 586
Parikh, S. V., Quilty, L. C., Ravitz, P., Rosenbluth, M., Pavlova, B., Grigoriadis, S., Velyvis, V., Kennedy, S. H., Lam, R. W., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659418 · Cited by 562
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Grossman, D. C., et al. (2019) · JAMA · doi:10.1001/jama.2019.0007 · Cited by 494
Conway, C. R., George, M. S., & Sackeim, H. A. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2586 · Cited by 244
Randomized discontinuation trials: Utility and efficiency
Kopec, J. A., Abrahamowicz, M., & Esdaile, J. M. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90163-u · Cited by 134
van Bronswijk, S., Moopen, N., Beijers, L., Ruhe, H. G., & Peeters, F. (2019) · Psychological Medicine · doi:10.1017/s003329171800199x · Cited by 128
Stephens, S., Ford, E., Paudyal, P., & Smith, H. (2016) · The Annals of Family Medicine · doi:10.1370/afm.1967 · Cited by 109 · cited 2×
“Journal of clinical epidemiology 1993; 46(9): 959-71.”
Background
Cited by
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications
Li, Z., Ruan, M., Chen, J., & Fang, Y. (2021) · Neuroscience Bulletin · doi:10.1007/s12264-021-00638-3 · Cited by 326
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
A Look at the Importance of Chirality in Drug Activity: Some Significative Examples
Ceramella, J., Iacopetta, D., Franchini, A., Luca, M. D., Saturnino, C., Andreu, I., Sinicropi, M. S., & Catalano, A. A. (2022) · Applied Sciences · doi:10.3390/app122110909 · Cited by 175
Metadata
- Authors
- Cristea, I. A., & Naudet, F.
- Affiliations
- University of Pavia (IT)
- Inserm (FR)
- Corresponding author
- Cristea, Ioana A
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 6
- Issue
- 12
- Pages
- 975-977
- ISSN
- 2215-0366 (ISSN-L)
- OpenAlex
- W2983463140
- Cited by
- 98
- References
- 11
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 14 · 2023: 22 · 2022: 9 · 2021: 21 · 2020: 16
- FWCI
- 7.32
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- esketamine, brexanolone, treatment-resistant depression, postpartum depression, FDA drug approval, antidepressants, breakthrough therapy designation, risk-benefit assessment, clinical trial data transparency, NIMBYism, mental health policy, access to mental health care, mental health workforce shortage, mental health funding, mental health advocacy
- MeSH terms
- Antidepressive Agents, Drug Combinations, Female, Humans, Ketamine, Pregnanolone, United States, United States Food and Drug Administration, Depression, Postpartum, beta-Cyclodextrins, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: US Food and Drug Administration approval of esketamine and brexanolone. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30292-5
- The paper
- Cristea, I. A., & Naudet, F. (2019). US Food and Drug Administration approval of esketamine and brexanolone. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30292-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.